A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
Latest Information Update: 21 Mar 2025
At a glance
- Drugs AZD 5004 (Primary)
- Indications Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 17 Mar 2025 Planned End Date changed from 22 Oct 2025 to 21 Oct 2025.
- 17 Mar 2025 Planned primary completion date changed from 22 Oct 2025 to 21 Oct 2025.
- 11 Feb 2025 New trial record